Global Monoclonal Antibodies Market Analysis & Outlook to 2022: Projected to Expand at a CAGR of Approx 15% with AbbVie, Amgen, Johnson & Johnson and Merck Leading - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Jan 3, 2019--The “Global Monoclonal Antibodies Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.
The monoclonal antibodies market will register a CAGR of about 15% by 2022.
Rise in the number of companies venturing into monoclonal antibodies space to drive market growth. To gain profits, the companies are investing huge amounts in the development of monoclonal antibodies. At present, companies are expanding their businesses to increase the development and sales of monoclonal antibodies.
Introduction of low cost biosimilar monoclonal antibodies
The introduction of biosimilars aimed at curbing the increasing year-over-year cost of healthcare and handling the economic pressure from the patient pool and governments to reduce healthcare expenses, could be instrumental in reducing the cost of medication and increasing patient access to treatment.
High cost of monoclonal antibodies
Monoclonal antibodies cost high, both at end-user stage as well as the development stage, primarily owing to the use of highly advanced and expensive facilities.
Key PlayersAbbVie Amgen Johnson & Johnson Merck
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: MARKET LANDSCAPEMarket ecosystem Market characteristics Market segmentation analysis
PART 05: PIPELINE ANALYSIS
PART 06: MARKET SIZINGMarket definition Market sizing 2017 Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
PART 08: MARKET SEGMENTATION BY APPLICATIONSegmentation by application Comparison by application Oncology - Market size and forecast 2017-2022 Immunology - Market size and forecast 2017-2022 Hematology - Market size and forecast 2017-2022 Others - Market size and forecast 2017-2022 Market opportunity by application
PART 09: MARKET SEGMENTATION BY ORIGIN OF MONOCLONAL ANTIBODIESSegmentation by origin of monoclonal antibodies Murine antibodies Human antibodies Humanized antibodies Chimeric antibodies
PART 10: CUSTOMER LANDSCAPE
PART 11: REGIONAL LANDSCAPE
PART 12: DECISION FRAMEWORK
PART 13: DRIVERS AND CHALLENGES
PART 14: MARKET TRENDSIncreasing cases of diseases like cancer and immunological disorders Rise in the number of companies venturing into the monoclonal antibodies space Growing pricing pressure in the monoclonal antibodies segment
PART 15: VENDOR LANDSCAPE
PART 16: VENDOR ANALYSISVendors covered Vendor classification Market positioning of vendors AbbVie Amgen Johnson & Johnson Merck
For more information about this report visit https://www.researchandmarkets.com/research/pbhv4m/global_monoclonal?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190103005307/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Immune Disorders Drugs,Biopharmaceuticals
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 01/03/2019 06:15 AM/DISC: 01/03/2019 06:15 AM